| Document |
Document Title |
|
WO/2000/059472A1 |
Formulations of intravenous anesthetic propofol emulsions are provided which produce a stable emulsion and simultaneously inhibit microbial growth thereby providing protection against accidental microbial contamination during long-term I...
|
|
WO/2000/059483A2 |
The present invention relates to the field of transdermal drug delivery. More specifically, the present invention relates to drug reservoir materials for use in transdermal drug delivery devices. The drug reservoirs of the present invent...
|
|
WO/2000/057877A1 |
This invention relates to compounds having Formula (I) or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Het and R¿5?-R¿13? are set in the specification. The invention also is directed to the use of compounds o...
|
|
WO/2000/051981A1 |
Aminocycloalkyl cinnamide compounds (I) are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of $i(in vitro) and $i(in vivo) uses for the compo...
|
|
WO/2000/048572A1 |
Disclosed are compounds of general formula (I) that function as prodrugs, thereby increasing bioavailabilities of the linked therapeutic agents, wherein the LINKER is (i) substituted or unsubstituted alkyl, (ii) substituted or unsubstitu...
|
|
WO/2000/047149A1 |
The present invention, which addresses the needs of the prior art, provides irreversible, hydrophilic gels which can be incorporated into dressing compositions, dermatologically compatible compositions, wound packings, wound dressings, b...
|
|
WO/2000/045791A2 |
A method of preparing liposomes to a selected particle size is described. In the method, a vesicle-forming lipid dissolved in a lipid solvent is hydrated with a second solvent to form a hydration mixture having greater than 10 and less t...
|
|
WO/2000/045832A2 |
The present invention concerns uses of compounds which modulate Delta-Sleep Inducing Peptide active for regulating anaesthesia and methods of evaluating the anaesthetic needs of a subject comprising assaying a sample taken from the subje...
|
|
WO/2000/044350A1 |
The invention deals with the transport of preferably large molecules across nasal mucosa by means of specially designed, highly adaptable carriers loaded with said molecules. One of the purposes of making such formulations is to achieve ...
|
|
WO/2000/042989A2 |
A process for producing a small-sized, lipid-based cochleate is described. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based...
|
|
WO/2000/038678A1 |
The invention concerns a composition, as medicine, consisting of at least two different active agents, having at least an activity with respect to neuroreceptors $g(a)¿2?; an activity with respect to NMDA neuroreceptors; an activity wit...
|
|
WO/2000/038684A1 |
A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having formula (I), and pharmaceuticall...
|
|
WO/2000/037047A1 |
A new composition set and a kit for use by intraocular operations, preferably cataract operations. The composition set comprises a first and a second viscoelastic agent, e.g. sodium hyaluronate, containing an anaesthetic, e.g. lidocaine ...
|
|
WO/2000/032584A2 |
The invention relates to the use of compounds of general formula (I), wherein A, B, A, Ar, R?1¿, R?2¿ and R?3¿ have the meanings detailed more closely in the description, for producing medicaments with an antiinflammatory action. The ...
|
|
WO/2000/030615A1 |
Sub-micron and micron-size stable particles of water-insoluble or poorly soluble drugs or other industrially useful insoluble compounds suspended in an aqueous medium containing at least one surface modifier are prepared by selecting the...
|
|
WO/2000/027369A1 |
The present invention relates to pharmaceutical compositions for the sustained release of pharmacologically active compounds, and methods of their manufacture and use. The pharmaceutical compositions contain microcrystals of pharmacologi...
|
|
WO/2000/027407A1 |
The invention relates to an injectable anesthetic containing particles with a lipophilic gas. Argon, krypton, xenon, nitrous oxide or mixtures of at least two of these gases are for example used as the lipophilic gas. Microparticles, mic...
|
|
WO/2000/027406A1 |
The inventive injectable anesthetic contains a hydrophilic liquid comprising a lipophilic gas. Argon, krypton, xenon, nitrous oxide or mixtures of at least two of these gases are used as the lipophilic gas. The lipophilic gas is preferab...
|
|
WO/2000/025785A1 |
A plastics container containing a sterile aqueous solution of an acid addition salt of a 1- alkyl-N- (2,6- dimethylphenyl)- 2-piperidinecarboxamide, wherein the solution is buffered.
|
|
WO/2000/024376A1 |
The present invention is directed to a sterile pharmaceutical composition comprising a propofol containing oil-in-water emulsion formulation having as an antimicrobial agent, a member selected from the group consisting of benzyl alcohol ...
|
|
WO/2000/023050A1 |
A sterile pharmaceutical composition for parenteral administration comprising an oil-in-water emulsion of propofol and an amount of pentetate sufficient to prevent significant growth of microorganisms for at least 24 hours after adventit...
|
|
WO/2000/021520A2 |
The invention relates to a pharmaceutical preparation, especially for oral administration, having at least one active substance and formulation components influencing the release of the active substance. Said preparation comprises at lea...
|
|
WO/2000/018369A1 |
Iontophoretic devices for the delivery of N-phenyl-N-(4-piperidinyl)amide esters are provided. The N-phenyl-N-(4-piperidinyl)amide esters are compounds of: A reservoir comprising a matrix material and, distributed in said matrix material...
|
|
WO/2000/018400A1 |
The present invention relates to a method for obtaining analgesia by administering 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enetiomer or pharmaceutically acceptable ester or salt thereof to a mammal intraspinally. 3-(1H-imidazol-4-ylme...
|
|
WO/2000/015167A1 |
Compositions and methods for treating wounds to significantly reduce the healing time, reduce the incidence of scar formation, improve the success of skin grafts, reduce the inflammatory response and providing anti-bacterial treatments t...
|
|
WO/2000/012067A1 |
The saccharinate salt of synthetic non-alkaloidal medicinal organic bases provides a novel salt form possessing improved organoleptic properties as well as reduced solubility.
|
|
WO/2000/010529A1 |
The present invention relates to a per oral, oral, or intranasal pharmaceutical mucoretentive, aqueous liquid composition comprising from about 2 % to about 50 %, by weight of the composition, of colloidal particles of silica, titanium d...
|
|
WO/2000/010528A1 |
The present invention relates to a per oral, oral or intranasal pharmaceutical mucoretentive, aqueous liquid composition comprising from about 2 % to about 50 %, by weight of the composition, of colloidal particles of silica, titanium di...
|
|
WO/2000/010531A1 |
A stable, sterile, and injectable aqueous dispersion of a water-insoluble microdroplet matrix of mean diameter from about 50 nm to about 1000 nm consisting essentially of between about 1 % to about 15 % of propofol; between about 1 % to ...
|
|
WO/2000/009089A1 |
Liposomal bupivacaine compositions are prepared using an ammonium sulfate gradient loading procedure, at a pH which prevents precipitation of the drug from the loading solution. Also described are liposome suspensions comprising 'GMV' (g...
|
|
WO/2000/007986A1 |
The application relates to substituted 2,3,3a,4,9,9a hexahydro-8-hydroxy-1H-benz[f]indole derivatives, to a method for the production thereof, and to their use as medicaments. The inventive indole derivatives correspond to general formul...
|
|
WO/2000/006142A1 |
The invention provides injectable formulations of propofol using N-methylpyrrolidone or 2-pyrrolidone as a solvent. Formulations of the invention are useful in all medical and veterinary indications when propofol is presently used. In ad...
|
|
WO/2000/005196A1 |
The present invention relates to $g(a)-amino acid phenyl ester derivatives having general formula (I) wherein R¿1? is (C¿1-3?)alkyloxy; R¿2? is (C¿1-3?)alkyl, (C¿1-3?)alkyloxy or (C¿2-3?)alkenyl; R¿3? is hydrogen, (C¿1-3?)alkyl, ...
|
|
WO/2000/003691A1 |
A system and method for implanting pellets containing local anesthetic agents into tissues of the heart for temporary treatment of angina pectoris. The mechanism of delivery can be transcatheter via chambers of the heart, endoscopic epic...
|
|
WO/2000/003716A1 |
A topical opioid paradigm was developed to determine analgesic peripheral effects of morphine. Topical morphine as well as peptides such as [D-Ala2,MePhe4,Gly(ol)5]enkephalin (DAMGO) produced a potent, dose-dependent analgesia using the ...
|
|
WO/1999/061023A1 |
The invention relates to novel compounds which show high affinity for cocaine receptors in the brain, particularly dopamine and serotonin transporter sites. The compounds may be used as imaging or pharmaceutical agents, in the diagnosis ...
|
|
WO1999051565A9 |
Novel compounds, pharmaceutical compositions and methods are disclosed for producing local anesthesia of long-duration. The compounds of this invention are multibinding compounds that comprise from 2 to 10 ligands covalently attached to ...
|
|
WO/1999/059553A1 |
The invention relates to effervescent preparations containing medicaments. According to the invention, preparations of this type are particularly stable in storage if they contain fusible sugar, sugar alcohol and/or a sugar substitute.
|
|
WO/1999/056725A1 |
The invention concerns fluid pharmaceutical compositions for controlled release of at least one active substance comprising: a) a therapeutically efficient amount of at least one active substance; b) 3 to 55 wt. % of phospholipid; c) 16 ...
|
|
WO/1999/056726A1 |
The invention concerns the use for treating periodontitis of a fluid pharmaceutical composition for controlled release of at least one active substance comprising: a) a therapeutically efficient amount of at least an active substance; b)...
|
|
WO/1999/055312A2 |
The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a nonadhesive backing layer, and the pharmaceutical may be provided in ...
|
|
WO1999039712A9 |
This invention is related to substituted semicarbazides represented by Formula (I) or a pharmaceutically acceptable salt or prodrug thereof, wherein: R1 and R2 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, a...
|
|
WO/1999/050225A1 |
Aminocyclohexyl ether compounds of formula (I), or a solvate or pharmaceutically acceptable salt thereof are disclosed. In said formula, A, X and R, -R¿5? have the meanings given in the description. The compounds of the present inventio...
|
|
WO/1999/039696A1 |
Sterile pharmaceutical compositions for parenteral administration containing 2, 6-diisopropylphenol (propofol) are described for use as anesthetics. The compositions comprise an oil-in-water emulsion of propofol additionally comprising a...
|
|
WO/1999/037301A1 |
The present invention is directed to the intramuscular use of ropivacaine for the manufacture of a medicament for use in the treatment of muskuloskeletal pain, in particular myofascial pain and tendinits.
|
|
WO/1999/036421A1 |
A compound of formula (I) or the pharmaceutically acceptable salts thereof, wherein R?1¿, R?2¿, R?3¿, R?4¿ and R?5¿ are defined above are useful as ORL1-receptor agonists, and useful as analgesics or the like in mammalian subjects.
|
|
WO/1999/036071A1 |
The invention herein relates to biodegradable polymer matrices for sustained delivery of anesthetics or more particularly, to a sustained release anesthetic preparation where fentanyl-based anesthetic is incorporated into a biodegradable...
|
|
WO/1999/036478A1 |
Glitter, at least a portion of which comprises color shifting film. The glitter is useful in any of a variety of ways, including in loose form, attached to the surface of a substrate, in a dispersible combination, or present in a matrix ...
|
|
WO/1999/032431A1 |
The present invention relates to a novel monophosphate salt of isopropyl-methyl-[2-(3-n-propoxyphenoxy)ethyl]amine. Moreover, the present invention also relates to a process for the preparation of the monophosphate salt of isopropyl-meth...
|
|
WO/1999/032430A1 |
The present invention relates to a novel process for the synthesis of isopropyl-methyl-[2-(3-n-propoxyphenoxy)ethyl]amine. Moreover, the present invention also relates to a novel intermediate and an optional purification step in the nove...
|
